Healthcare - Press Releases

SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- On February 15, 2025,Sanyou Bio conducted a full review of its Intelligent Super-trillion Molecule Discovery Platform. As the core technology of the platform, the intelligent super-trillion molecule library boasts a library capacity of up to 10 trillion, enabling the screening and identification of hundreds to thousands of lead molecules for a single target. By integrating high-through eukaryotic expression verification and multidimensional druggability analysis, the platform significantly improves the efficiency of innovative biological drug R&D and plays a key role in novel macromolecule drug discovery.

Agreement contributes to expanding access to cutting-edge genomic technologies and improving diagnostic efficacy

ORLANDO, Fla., Feb. 21, 2025 /PRNewswire/ -- CR Fitness Holdings LLC., the fastest-growing and leading franchisee of Crunch Fitness, announced the upcoming opening of Crunch Dr. Phillips, a $5 million, 37,080 square-foot state-of-the-art fitness facility. Projected to open in late Fall 2025, Crunch Dr. Phillips is located in the former World of Decor, 7506 Dr. Phillips Blvd.

DOHA, Qatar and NEW YORK, Feb. 23, 2025 /PRNewswire/ -- Deerfield Management today announced a collaboration with Qatar Investment Authority (QIA) as part of QIA's Fund of Funds program.

New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platforms

SAN DIEGO, Feb. 20, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora's registration statement issued in connection with Neumora's initial public offering (the "IPO") held on September 15, 2023, have until April 7, 2025 to seek appointment as lead plaintiff of the Neumora class action lawsuit. Captioned Chang v. Neumora Therapeutics, Inc., No. 25-cv-01072, and pending it the Southern District of New York, the Neumora class action lawsuit charges Neumora as well as certain of Neumora's top executives and directors, and certain underwriters of the IPO, with violations of the Securities Act of 1933.

BROOKLYN, N.Y., Feb. 20, 2025 /PRNewswire/ -- On or about September 19, 2024, Atlantis Operating LLC d/b/a The Phoenix Rehabilitation and Nursing Center ('Phoenix') learned of a data security incident involving a third party vendor, which may have impacted the personal information of current and/or past patients of Phoenix. Phoenix has since diligently worked to determine what happened and what information was involved as a result of this incident. Phoenix, consistent with industry standards, promptly launched an investigation and engaged experts to assist in assessing the scope of the incident. Based on information provided by the third party, it was determined the incident occurred between on or about July 20, 2024. Upon identification of the potentially impacted data set, efforts were then initiated to provide notice to the potentially impacted population.

Canada's Leading Medical Cannabis Company Broadens Innovative Product Portfolio to Growing Market in Australia

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination. The market growth is largely fueled by the increasing uptake of the influenza vaccine and government efforts to raise awareness and encourage vaccination.

Enhanced Women's Health Program Integrates Pelvic Floor Therapy and Menopause Care Through Partnership with Vira Health

FREMONT, Calif., Feb. 20, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of its Certified Service Provider (CSP) Program, designed to expand access to its cutting-edge NULISA assays in academia and biopharmaceutical research.

WINDHAM, N.H., Feb. 20, 2025 /PRNewswire/ --The United States is projected to face a shortage of up to 8,650 cardiologists by 2037, raising serious concerns about access to cardiovascular care. To help healthcare leaders navigate the growing workforce challenge, Medicus Healthcare Solutions has released a new white paper titled An Inside Look at the Cardiology Workforce: Shortages, Demand, and Strategic Responses.

HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in itsmulticenter, randomized, double-blind Phase III clinical trial of ivonescimab in combination with chemotherapy for first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) (HARMONi-BC1/AK112-308). Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by the company.

Auf dem 25. Wellness Congress stellte Nerio Alessandri in Anwesenheit von 2.000 Menschen aus 100 Lndern Healthness vor, die neue Vision, die die Zukunft von Wellness und Prvention revolutionieren wird.

LUND,Sweden, Feb. 21, 2025 /PRNewswire/ --Immunovia will publish its full year 2024 results on February 25, 2025 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com.

Bracco will present an immersive experience at its booth to educate congress attendees on the importance of corporate commitment to sustainability and how its MR imaging portfolio contributes to the progress of sustainable radiology.

Bracco Diagnostics Inc. (PRNewsFoto/Bracco Diagnostics Inc.) (PRNewsfoto/Bracco Group)

STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- SciBase Holding AB("SciBase") (STO: SCIB),a leading developer of augmented intelligence-based solutions for skin disordersannounced today, that an article comparing US and German dermatologists improved biopsy decisions following the addition of Nevisense (EIS) as a decision support tool was recently published in SKIN, the Journal of Cutaneous Medicine. The article compares two corresponding studies, one conducted in the US and one in Germany, with the aim to evaluate how Nevisense (EIS) impacted dermatologist's biopsy decisions. The findings were that for both groups the addition of dermoscopy and even more so Nevisense (EIS) as decision support tools significantly improved biopsy decision accuracy. Findings revealed that American dermatologists had a higher rate of correct biopsy decisions for malignant melanomas (MMs) compared to their German counterparts. However, German dermatologists showed greater accuracy in avoiding unnecessary biopsies of benign pigmented skin lesions.

HELLERUP,Denmark, Feb. 21, 2025 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately-held, clinical stage, pharmaceutical development company focused on immunology, today announced a poster presentation on new clinical data of oral orismilast in patients with UC at the 20thEuropean Crohn's and Colitis Organisation (ECCO) congress on February 19-22, 2025, in Berlin, Germany.

HELLERUP,Denmark, Feb. 21, 2025 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately-held, clinical stage, pharmaceutical development company focused on immunology, today announced a poster presentation on new clinical data of oral orismilast in patients with UC at the 20thEuropean Crohn's and Colitis Organisation (ECCO) congress on February 19-22, 2025, in Berlin, Germany.

STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- SciBase Holding AB("SciBase") (STO: SCIB),a leading developer of augmented intelligence-based solutions for skin disordersannounced today, that an article comparing US and German dermatologists improved biopsy decisions following the addition of Nevisense (EIS) as a decision support tool was recently published in SKIN, the Journal of Cutaneous Medicine. The article compares two corresponding studies, one conducted in the US and one in Germany, with the aim to evaluate how Nevisense (EIS) impacted dermatologist's biopsy decisions. The findings were that for both groups the addition of dermoscopy and even more so Nevisense (EIS) as decision support tools significantly improved biopsy decision accuracy. Findings revealed that American dermatologists had a higher rate of correct biopsy decisions for malignant melanomas (MMs) compared to their German counterparts. However, German dermatologists showed greater accuracy in avoiding unnecessary biopsies of benign pigmented skin lesions.

LEHI, UT. and LOUISVILLE,KY., Feb. 20, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY) ("Waystar"), a provider of leading healthcare payments software, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock by certain investment funds of EQT AB and Bain Capital, LP, and Canada Pension Plan Investment Board (CPP Investments), and their respective affiliates (collectively, the "Selling Stockholders") at a price to the public of $40.00 per share. Additionally, the Selling Stockholders have granted the underwriters a 30-day option to purchase up to 3,000,000 additional shares of common stock.Waystar is not selling any shares and will not receive any proceeds from the sale of shares in the offering by the Selling Stockholders. The offering is expected to close on or about February 24, 2025, subject to customary closing conditions.

STOCKHOLM, Feb. 21, 2025 /PRNewswire/ --

- En el 25 Congreso de Bienestar, ante 2.000 personas de 100 pases, Nerio Alessandri lanz Healthness, la nueva visin que revolucionar el futuro del bienestar y la prevencin

Global Financial Market Review (GFM) is a dedicated online news aggregation portal specializing in financial market news and industry updates. It combines original editorials with curated content from global news providers, reaching over 14 million readers annually. With a focus on reliability and depth, GFM has positioned itself as a trusted source in the financial sector, boasting a strong social media presence with over 180,000 Twitter followers.